Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Asian Stocks Slide as Oil Surge Fuels Rate Hike Fears 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Fitch Eyes Japan Budget for Fiscal Discipline 
Blackstone Eyes $2 Billion ZO Skin Health Sale 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Add as a preferred source on Google
Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.
